{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:19Z","timestamp":1792425679105,"version":"4.5.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["#17K16108"],"award-info":[{"award-number":["#17K16108"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["#17H04192"],"award-info":[{"award-number":["#17H04192"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan and Grants-in-Aid for Scientific Research"},{"name":"Ministry of Health, Labour and Welfare of Japan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aquaporin 4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) is an autoimmune astrocytopathic disease pathologically characterized by the massive destruction and regeneration of astrocytes with diverse types of tissue injury with or without complement deposition. However, it is unknown whether this diversity is derived from differences in pathological processes or temporal changes. Furthermore, unlike for the demyelinating lesions in multiple sclerosis, there has been no staging of astrocytopathy in AQP4-IgG+NMOSD based on astrocyte morphology. Therefore, we classified astrocytopathy of the disease by comparing the characteristic features, such as AQP4 loss, inflammatory cell infiltration, complement deposition and demyelination activity, with the clinical phase. We performed histopathological analyses in eight autopsied cases of AQP4-IgG+NMOSD. Cases comprised six females and two males, with a median age of 56.5\u2009years (range, 46\u201371\u2009years) and a median disease duration of 62.5\u2009months (range, 0.6\u2013252\u2009months). Astrocytopathy in AQP4-IgG+NMOSD was classified into the following four stages defined by the astrocyte morphology and immunoreactivity for GFAP: (i) astrocyte lysis: extensive loss of astrocytes with fragmented and\/or dust-like particles; (ii) progenitor recruitment: loss of astrocytes except small nucleated cells with GFAP-positive fibre-forming foot processes; (iii) protoplasmic gliosis: presence of star-shaped astrocytes with abundant GFAP-reactive cytoplasm; and (iv) fibrous gliosis: lesions composed of densely packed mature astrocytes. The astrocyte lysis and progenitor recruitment stages dominated in clinically acute cases (within 2\u2009months after the last recurrence). Findings common to both stages were the loss of AQP4, a decreased number of oligodendrocytes, the selective loss of myelin-associated glycoprotein and active demyelination with phagocytic macrophages. The infiltration of polymorphonuclear cells and T cells (CD4-dominant) and the deposition of activated complement (C9neo), which reflects the membrane attack complex, a hallmark of acute NMOSD lesions, were selectively observed in the astrocyte lysis stage (98.4% in astrocyte lysis, 1.6% in progenitor recruitment, and 0% in protoplasmic gliosis and fibrous gliosis). Although most of the protoplasmic gliosis and fibrous gliosis lesions were accompanied by inactive demyelinated lesions with a low amount of inflammatory cell infiltration, the deposition of complement degradation product (C3d) was observed in all four stages, even in fibrous gliosis lesions, suggesting the past or chronic occurrence of complement activation, which is a useful finding to distinguish chronic lesions in NMOSD from those in multiple sclerosis. Our staging of astrocytopathy is expected to be useful for understanding the unique temporal pathology of AQP4-IgG+NMOSD.<\/jats:p>","DOI":"10.1093\/brain\/awab102","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T07:47:04Z","timestamp":1615276024000},"page":"2401-2415","source":"Crossref","is-referenced-by-count":98,"title":["Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders"],"prefix":"10.1093","volume":"144","author":[{"given":"Yoshiki","family":"Takai","sequence":"first","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Sendai Medical Center, Sendai 983-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"},{"name":"Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa 992-1202, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo 060-0808, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[{"name":"Department of neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sasou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross Society Hachinohe Hospital, Hachinohe 039-1104, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Namatame","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"},{"name":"Department of Neurology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki 986-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"},{"name":"Department of Neurology, South Miyagi Medical Center, Shibata 989-1253, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lassmann","sequence":"additional","affiliation":[{"name":"Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna A-1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"},{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Itoyama","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare, Fukuoka 814-0001, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"4","key":"2021090418515378800_awab102-B1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"2021090418515378800_awab102-B2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","article-title":"Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica","volume":"210","author":"Takahashi","year":"2006","journal-title":"Tohoku J Exp Med"},{"issue":"9","key":"2021090418515378800_awab102-B3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"4","key":"2021090418515378800_awab102-B4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00004647-200204000-00001","article-title":"Aquaporins in brain: Distribution, physiology, and pathophysiology","volume":"22","author":"Badaut","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"2021090418515378800_awab102-B5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1152\/physrev.00011.2013","article-title":"Physiological roles of aquaporin-4 in brain","volume":"93","author":"Nagelhus","year":"2013","journal-title":"Physiol Rev"},{"issue":"4","key":"2021090418515378800_awab102-B6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2021090418515378800_awab102-B7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/WNR.0b013e32832776f4","article-title":"Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum","volume":"20","author":"Kinoshita","year":"2009","journal-title":"Neuroreport"},{"issue":"17","key":"2021090418515378800_awab102-B8","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J Biol Chem"},{"key":"2021090418515378800_awab102-B9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurol"},{"issue":"5","key":"2021090418515378800_awab102-B10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"2021090418515378800_awab102-B11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"Pt 2","key":"2021090418515378800_awab102-B12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"Pt 7","key":"2021090418515378800_awab102-B13","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"Pt 5","key":"2021090418515378800_awab102-B14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: Distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"issue":"10","key":"2021090418515378800_awab102-B15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/1352458510382324","article-title":"Neuromyelitis optica: A demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes","volume":"16","author":"Parratt","year":"2010","journal-title":"Mult Scler"},{"issue":"6","key":"2021090418515378800_awab102-B16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","article-title":"Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica","volume":"125","author":"Misu","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2021090418515378800_awab102-B17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s00415-014-7277-z","article-title":"MOG-IgG in neuromyelitis optica","volume":"261","author":"Luppe","year":"2014","journal-title":"J Neurol"},{"issue":"6","key":"2021090418515378800_awab102-B18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"2021090418515378800_awab102-B19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2021090418515378800_awab102-B20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1352458514551455","article-title":"Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody","volume":"21","author":"Ikeda","year":"2015","journal-title":"Mult Scler"},{"issue":"1","key":"2021090418515378800_awab102-B21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"Peschl","year":"2017","journal-title":"J Neuroinflamm"},{"issue":"5","key":"2021090418515378800_awab102-B22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"Pt 5","key":"2021090418515378800_awab102-B23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"issue":"5","key":"2021090418515378800_awab102-B24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1750-3639.2011.00475.x","article-title":"Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients","volume":"21","author":"Matsuoka","year":"2011","journal-title":"Brain Pathol"},{"issue":"2","key":"2021090418515378800_awab102-B25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"2021090418515378800_awab102-B26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","article-title":"An updated histological classification system for multiple sclerosis lesions","volume":"133","author":"Kuhlmann","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2021090418515378800_awab102-B27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0165-5728(98)00031-9","article-title":"Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna","volume":"86","author":"Lassmann","year":"1998","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2021090418515378800_awab102-B28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2990.2000.00217.x","article-title":"Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS","volume":"26","author":"van der Valk","year":"2000","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"2021090418515378800_awab102-B29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.23621","article-title":"Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate","volume":"72","author":"Bruck","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"2021090418515378800_awab102-B30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"issue":"2","key":"2021090418515378800_awab102-B31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/glia.23090","article-title":"Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis","volume":"65","author":"Michailidou","year":"2017","journal-title":"Glia"},{"key":"2021090418515378800_awab102-B32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","article-title":"Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease","volume":"3","author":"Fujihara","year":"2012","journal-title":"Clin Exp Neuroimmunol"},{"issue":"1-2","key":"2021090418515378800_awab102-B33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2011.02.018","article-title":"Neuromyelitis optica and astrocytic damage in its pathogenesis","volume":"306","author":"Fujihara","year":"2011","journal-title":"J Neurol Sci"},{"issue":"3","key":"2021090418515378800_awab102-B34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"2021090418515378800_awab102-B35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00401-013-1220-8","article-title":"Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions","volume":"127","author":"Wrzos","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2021090418515378800_awab102-B36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann Neurol"},{"issue":"4","key":"2021090418515378800_awab102-B37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"8","key":"2021090418515378800_awab102-B38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"2021090418515378800_awab102-B39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2021090418515378800_awab102-B40","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1172\/JCI65861","article-title":"Detection of complement activation using monoclonal antibodies against C3d","volume":"123","author":"Thurman","year":"2013","journal-title":"J Clin Investig"},{"issue":"2","key":"2021090418515378800_awab102-B41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","article-title":"Regulation of humoral immunity by complement","volume":"37","author":"Carroll","year":"2012","journal-title":"Immunity"},{"issue":"1-3","key":"2021090418515378800_awab102-B42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/IR:36:1:197","article-title":"Complement-mediated activation of the adaptive immune responses: Role of C3d in linking the innate and adaptive immunity","volume":"36","author":"Toapanta","year":"2006","journal-title":"Immunol Res"},{"issue":"6029","key":"2021090418515378800_awab102-B43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1201954","article-title":"A crystal structure of the complex between human complement receptor 2 and its ligand C3d","volume":"332","author":"van den Elsen","year":"2011","journal-title":"Science"},{"issue":"7638","key":"2021090418515378800_awab102-B44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"2021090418515378800_awab102-B45","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/glia.23814","article-title":"The effects of A1\/A2 astrocytes on oligodendrocyte linage cells against white matter injury under prolonged cerebral hypoperfusion","volume":"68","author":"Miyamoto","year":"2020","journal-title":"Glia"},{"issue":"9","key":"2021090418515378800_awab102-B46","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3390\/ijms17091407","article-title":"Efficacy of polyvalent human immunoglobulins in an animal model of neuromyelitis optica evoked by intrathecal anti-aquaporin 4 antibodies","volume":"17","author":"Grunewald","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2021090418515378800_awab102-B47","first-page":"45","article-title":"Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica","volume":"7","author":"Nishiyama","year":"2016","journal-title":"Biochem Biophys Rep"},{"key":"2021090418515378800_awab102-B48","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fimmu.2018.01438","article-title":"Aquaporin-4 autoantibodies from neuromyelitis optica spectrum disorder patients induce complement-independent immunopathologies in mice","volume":"9","author":"Yick","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2021090418515378800_awab102-B49","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"2021090418515378800_awab102-B50","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00415-016-8138-8","article-title":"Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder","volume":"263","author":"Jeong","year":"2016","journal-title":"J Neurol"},{"issue":"12","key":"2021090418515378800_awab102-B51","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","article-title":"Retinal ganglion cell loss in neuromyelitis optica: A longitudinal study","volume":"89","author":"Oertel","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021090418515378800_awab102-B52","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2019.00608","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: A review of clinical and neuroradiological features","volume":"10","author":"Oertel","year":"2019","journal-title":"Front Neurol"},{"key":"2021090418515378800_awab102-B53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.brainresbull.2017.02.011","article-title":"The role of aquaporin-4 in synaptic plasticity, memory and disease","volume":"136","author":"Hubbard","year":"2018","journal-title":"Brain Res Bull"},{"issue":"1","key":"2021090418515378800_awab102-B54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann Neurol"},{"key":"2021090418515378800_awab102-B55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.expneurol.2014.12.015","article-title":"The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model","volume":"265","author":"Geis","year":"2015","journal-title":"Exp Neurol"},{"issue":"9","key":"2021090418515378800_awab102-B56","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1093\/brain\/awaa227","article-title":"Connexins in neuromyelitis optica: A link between astrocytopathy and demyelination","volume":"143","author":"Richard","year":"2020","journal-title":"Brain"},{"issue":"3","key":"2021090418515378800_awab102-B57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00401-018-1950-8","article-title":"Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat","volume":"137","author":"Hillebrand","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2021090418515378800_awab102-B58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(15)00313-0","article-title":"The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research","volume":"15","author":"Hohlfeld","year":"2016","journal-title":"Lancet Neurol"},{"issue":"7","key":"2021090418515378800_awab102-B59","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"issue":"9","key":"2021090418515378800_awab102-B60","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: A cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2021090418515378800_awab102-B61","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","article-title":"Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein","volume":"18","author":"Herges","year":"2012","journal-title":"Mult Scler"},{"issue":"7","key":"2021090418515378800_awab102-B62","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.20080159","article-title":"IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition","volume":"205","author":"Kroenke","year":"2008","journal-title":"J Exp Med"},{"issue":"9","key":"2021090418515378800_awab102-B63","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2021090418515378800_awab102-B64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: Pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol"},{"key":"2021090418515378800_awab102-B65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2017.03.006","article-title":"Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica","volume":"469","author":"Uzawa","year":"2017","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2021090418515378800_awab102-B66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"22","key":"2021090418515378800_awab102-B67","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awab102\/39312352\/awab102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/144\/8\/2401\/40306012\/awab102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/144\/8\/2401\/40306012\/awab102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T15:28:53Z","timestamp":1697988533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/144\/8\/2401\/6169159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,3,12]]},"published-print":{"date-parts":[[2021,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awab102","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,3,12]]}}}